IA
TCRT icon

IFG Advisory’s Alaunos Therapeutics TCRT Stock Holding History

IFG Advisory’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14 Buy
+6
New +$15 ﹤0.01% 2348

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IFG Advisory's TCRT Position: Q2 2026 in Review

IFG Advisory opened a new position in Alaunos Therapeutics (TCRT) in Q2 2026: 6 shares worth $14. The stake represents ﹤0.01% of the portfolio and ranks #2348 among its holdings.

29 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

  • IFG Advisory held 6 shares of Alaunos Therapeutics worth $14 as of Q2 2026.
  • Alaunos Therapeutics was a new IFG Advisory position in Q2 2026.
  • Alaunos Therapeutics made up ﹤0.01% of IFG Advisory's portfolio in Q2 2026, its #2348 holding.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.